Aromatase inhibitors: prediction of response and nature of resistance

Bibliography

• Early Breast Cancer Trialists Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717
   PubMedGoogle Scholar
• Winer EP, Hudis C, Burstein HJ, American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005;23:619-29
   PubMed Web of Science ®Google Scholar
• Miller WR. Aromatase inhibitors and breast cancer. Minerva Endocrinol 2006;31:27-46
   PubMedGoogle Scholar
• Lonning PE. Pharmacology of new aromatase inhibitors. Breast 1996;5:202-6
   Web of Science ®Google Scholar
• Geisler J, Haynes B, Anker G, Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 2002;20:751-7
   PubMed Web of Science ®Google Scholar
• Dowsett M. Preoperative models to evaluate endocrine strategies for breast cancer. Clin Cancer Res 2003;9:502-10s
   Google Scholar
• Anderson TJ, Dixon JM, Stuart M, Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002;87:334-8
   PubMed Web of Science ®Google Scholar
• Dixon JM. Neoadjuvant therapy: surgical perspectives. In: Miller WR, Ingle JN, editors, Endocrine therapy in breast cancer. Marcel Dekker, New York; 2002. p. 197-212
   Google Scholar
• Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert Opin Investig Drugs 2003;12:1-12
   PubMedGoogle Scholar
• ATAC (Arimidex, Tamoxifen Alone or in Combination) Trialists Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:2131-9
   PubMedGoogle Scholar
• Goss PE, Ingle JN, Martino S, Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-9
   PubMed Web of Science ®Google Scholar
• Coombes RC, Kilburn LS, Snowdon CF, Survival and safety of exemestane versus tamoxifen after 2 – 3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;365:559-70
   Google Scholar
• Eiermann W, Paepke S, Appfelstaedt J, Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 2001;12:1527-32
   PubMed Web of Science ®Google Scholar
• Smith IE, Dowsett M, Ebbs SR, Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:5108-16
   PubMed Web of Science ®Google Scholar
• Semiglazov V, Kletsel A, Semiglazov V, Exemestane (E) versus tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0) [abstract 530]. J Clin Oncol 2005;23(16 Suppl):11s
   PubMedGoogle Scholar
• Mouridsen H, Gershanovich M, Sun Y, Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-9
   PubMed Web of Science ®Google Scholar
• Johnston SR, Martin LA, Head J, Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005;95:173-81
   PubMed Web of Science ®Google Scholar
• Jonat W, Gnant M, Boccardo F, Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991-6
   PubMed Web of Science ®Google Scholar
• Dowsett M, Cuzick J, Ingle J, Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010;28(3):509-18
   PubMed Web of Science ®Google Scholar
• Miller WR. Prediction of estrogen sensitivity/dependence. In: Miller WR, editor, Estrogen and breast cancer. RG Landes, Austen, TX; 1996. p. 151-70
   Google Scholar
• Dixon JM. Prospects of neoadjuvant aromatase inhibitor therapy in breast cancer. Expert Rev Anticancer Ther 2008;8:453-63
   PubMed Web of Science ®Google Scholar
• Kaufmann M, von Minckwitz G, Bear HD, Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. Ann Oncol 2007;18:1927-34
   PubMed Web of Science ®Google Scholar
• Ma CX, Ellis MJ. Neoadjuvant endocrine therapy for locally advanced breast cancer. Semin Oncol 2006;33:650-6
   PubMed Web of Science ®Google Scholar
• Murray J, Miller WR, Dixon JM. Neoadjuvant endocrine therapy models. Methods Mol Med 2006;120:489-502
   PubMedGoogle Scholar
• Macaskill EJ, Dixon JM. Neoadjuvant use of endocrine therapy in breast cancer. Breast J 2007;13:243-50
   PubMedGoogle Scholar
• Miller WR, Larionov A, Renshaw L, Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009;27:1382-7
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov AA, Renshaw L, Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole. Pharmacogenet Genomics 2007;17:813-26
   PubMed Web of Science ®Google Scholar
• Forouhi P, Walsh JS, Anderson TJ, Chetty U. Ultrasonography as a method of measuring breast tumour size and monitoring response to primary systemic treatment. Br J Surg 1994;81:223-5
   PubMed Web of Science ®Google Scholar
• Kuerer HM, Newman LA, Smith TL, Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicinbased neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-9
   PubMed Web of Science ®Google Scholar
• Dixon JM, Love CD, Renshaw L, Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr Relat Cancer 1999;6:227-30
   PubMed Web of Science ®Google Scholar
• Sasano H, Suzuki T, Moriya T. Pathology of breast cancer following neoadjuvant therapy. In: Miller WR, Ingle JN, editors, Endocrine therapy in breast cancer. Marcel Dekker, New York; 2002. p. 213-22
   Google Scholar
• Anderson TJ, Dixon JM, Stuart M, Effect of neoadjuvant treatment with anastrozole on tumour histology in postmenopausal women with large operable breast cancer. Br J Cancer 2002;87:334-8
   PubMed Web of Science ®Google Scholar
• Miller WR, Dixon JM, MacFarlane L, Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 2003;39:462-8
   PubMedGoogle Scholar
• Miller WR, Dixon JM, Cameron DA, Anderson TJ. Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy. J Steroid Biochem Mol Biol 2001;79:103-7
   PubMedGoogle Scholar
• Miller WR, White S, Dixon JM, Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole. Br J Cancer 2006;94:1051-6
   PubMedGoogle Scholar
• Dowsett M, Smith IE, Ebbs SR, Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res 2005;11:S951-8
   PubMed Web of Science ®Google Scholar
• Tao Y, Klause A, Vickers A, Clinical and biomarker endpoint analysis in neoadjuvant endocrine therapy trials. J Steroid Biochem Mol Biol 2005;95:91-5
   PubMedGoogle Scholar
• Dowsett M, Salter J, Hills M, Short-term presurgical treatment for all? Breast Cancer Res 2007;9(Suppl 2):S13
   Google Scholar
• Itoh T, Karlsberg K, Kijima I, Letrozole-, anastrozole- and tamoxifen-responsive genes in MCF-7aro cells: a microarray approach. Mol Cancer Res 2005;3:203-18
   PubMed Web of Science ®Google Scholar
• Harvey HA. Emerging role of aromatase inhibitors in the treatment of breast cancer. Oncology 1998;12:32-5
   PubMedGoogle Scholar
• Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-42
   PubMed Web of Science ®Google Scholar
• Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer. Cancer 2008;113:2385-97
   PubMed Web of Science ®Google Scholar
• Johnston SRD. Advanced disease and resistance modulation. In: Ellis MJ, editor, Aromatase inhibitors for the treatment of breast cancer. CMP Healthcare Media, New York; 2005. p. 73-90
   Google Scholar
• Miller WR, Bartlett J, Brodie AM, Aromatase inhibitors: are there differences between steroidal and nonsteroidal aromatase inhibitors and do they matter? Oncologist 2008;13:829-37
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Dowsett M. Aromatase inhibitors for breast cancer: lessons from the laboratory. Nat Rev Cancer 2003;3:821-31
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Sutherland RL. Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 2009;9:631-43
   PubMed Web of Science ®Google Scholar
• Elledge RM, Osborne CK. Oestrogen receptors and breast cancer. BMJ 1997;314(7098):1843-4
   Google Scholar
• Dowsett M. Biology of estrogen-dependent breast cancer. In: Ellis MJ, editor, Aromatase inhibitors for the treatment of breast cancer. CMP Healthcare Media, New York; 2005. p. 1-13
   Google Scholar
• Ma CX, Sanchez CG, Ellis MJ. Predicting endocrine therapy responsiveness in breast cancer. Oncology (Williston Park) 2009;23:133-42
   PubMedGoogle Scholar
• Miller WR, Anderson TJ, Iqbal S, Dixon JM. Neoadjuvant therapy: prediction of response. In: Miller WR, Ingle JN, editors, Endocrine therapy in breast cancer. Marcel Dekker, New York; 2002. p. 223-9
   Google Scholar
• Elledge RM, Green S, Pugh R, Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study. Int J Cancer 2000;89:111-17
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Coop A, Singh B, Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:3808-16
   PubMed Web of Science ®Google Scholar
• Fuqua SA, Allred DC, Elledge RM, The ER-positive/PgR-negative breast cancer phenotype is not associated with mutations within the DNA binding domain. Breast Cancer Res Treat 1993;26:191-202
   PubMedGoogle Scholar
• Masiakowski P, Breathnach R, Bloch J, Cloning of cDNA sequences of hormone regulated genes from MCF-7 human breast cancer cell line. Nucleic Acids Res 1982;10:7895-903
   PubMed Web of Science ®Google Scholar
• Mackay A, Urruticoechea A, Dixon JM, Molecular response to aromatase inhibitor treatment in primary breast cancer. Breast Cancer Res 2007;9:R37
   PubMed Web of Science ®Google Scholar
• Dowsett M, Houghton J, Iden C, Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status. Ann Oncol 2006;17:818-26
   PubMed Web of Science ®Google Scholar
• Dowsett M, Ebbs SR, Dixon JM, Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: influence of hormonal status and HER-2 in breast cancer – a study from the IMPACT trialists. J Clin Oncol 2005;23:2477-92
   PubMed Web of Science ®Google Scholar
• Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6
   PubMed Web of Science ®Google Scholar
• Generali D, Buffa FM, Berruti A, Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol 2009;27:227-34
   PubMed Web of Science ®Google Scholar
• Yamashita H, Takahashi S, Ito Y, Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 2009;100:2028-33
   PubMedGoogle Scholar
• Buyse M, Loi S, van't Veer L, Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 2006;98:1183-92
   PubMed Web of Science ®Google Scholar
• Sparano JA, Paik S. Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 2008;26:721-8
   PubMed Web of Science ®Google Scholar
• Miller WR, Larionov A, Anderson TJ, Predicting response and resistance to endocrine therapy: profiling patients on aromatase inhibitors. Cancer 2008;112(3 Suppl):689-94
   PubMedGoogle Scholar
• Dowsett M, Johnston S, Martin LA, Growth factor signalling and response to endocrine therapy: the Royal Marsden experience. Endocr Relat Cancer 2005;12(Suppl 1):S113-17
   Google Scholar
• Shim WS, Conaway M, Masamura S, Estradiol hypersensitivity and MAP kinase expression in long term estrogen deprived human breast cancer cells in vivo. Endocrinology 2000;141:396-405
   PubMed Web of Science ®Google Scholar
• Chan CM, Martin LA, Johnston SR, Molecular changes associated with the acquisition of oestrogen hypersensitivity in MCF-7 breast cancer cells on long-term oestrogen deprivation. J Steroid Biochem Mol Biol 2002;81:333-41
   PubMed Web of Science ®Google Scholar
• Martin LA, Farmer I, Johnston SR, Enhanced estrogen receptor (ER) alpha, ERBB2, and MAPK signal transduction pathways operate during the adaptation of MCF-7 cells to long term estrogen deprivation. J Biol Chem 2003;278:30458-68
   PubMed Web of Science ®Google Scholar
• Masri S, Phung S, Wang X, Genome-wide analysis of aromatase inhibitor-resistant, tamoxifen-resistant, and long-term estrogen-deprived cells reveals a role for estrogen receptor. Cancer Res 2008;68:4910-18
   PubMedGoogle Scholar
• Geisler J, Lonning PE. Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. Clin Breast Cancer 2001;1:297-308
   PubMedGoogle Scholar
• Perey L, Paridaens R, Nole F, Fulestrant as hormonal treatment in postmenopausal women with advanced breast cancer progressing after treatment with tamoxifen and aromatase inhibitors: update of a phase II SAKK trial. Breast Cancer Res Treat 2004;18:S236
   Google Scholar
• Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004;90(Suppl 1):S15-S18
   Google Scholar
• Miller WR. Controversies in breast cancer 2008. Breast Cancer Res 2008;10(Suppl 4):S1
   Google Scholar
• Miller WR, Larionov A, Renshaw L, Aromatase inhibitors – gene discovery. J Steroid Biochem Mol Biol 2007;106:130-42
   PubMedGoogle Scholar
• Thurlimann B, Paridaens R, Serin D, Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimde: a phase II multicentre multi-national trial. Eur J Cancer 1997;33:1767-73
   PubMed Web of Science ®Google Scholar
• Ingle JN. Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer. Breast Cancer Res 2008;10(Suppl 4):S17
   Google Scholar
• Santen RJ, Misbin RI. Aminoglutethimide: review of pharmacology and clinical use. Pharmacology 1981;1:95-120
   Google Scholar
• Dowsett M, Pfister C, Johnston SRD, Impact of tamoxifen on the pharmacokinetics and endocrine effects of the aromatase inhibitor letrozole in postmenopausal women with breast cancer. Clin Cancer Res 1999;5:2338-43
   PubMed Web of Science ®Google Scholar
• Dowsett M, Tobias JS, Howell A, The effect of anastrozole on the pharmacokinetics of tamoxifen in post-menopausal women with early breast cancer. Br J Cancer 1999;79:311-15
   PubMed Web of Science ®Google Scholar
• ATAC Trialists Group. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: sub-protocol of the ‘Arimidex TM and Tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317-24
   PubMedGoogle Scholar
• Lazarus P, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: focus on tamoxifen and aromatase inhibitors. Drug Metab Rev 2010;42:176-88
   Google Scholar
• Goss PE, Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin Cancer Res 2004;10:372S-9S
   PubMed Web of Science ®Google Scholar
• Miller WR. Biological rationale for endocrine therapy in breast cancer. Best Pract Res Clin Endocrinol Metab 2004;18:1-32
   PubMed Web of Science ®Google Scholar
• Kadohama N, Yarborough C, Zhou D, Kinetic properties of aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their interactions with aromatase inhibitors. J Steroid Biochem Mol Biol 1992;43:693-701
   PubMed Web of Science ®Google Scholar
• Miller WR. In vitro and in vivo effects of 4-hydroxyandrostenedione on steroid and tumour metabolism. In: Coombes RC, Dowsett M, editors, 4-hydroxyandrostenedione – A new approach to hormone-dependent cancer. Royal Society of Medicine Services Ltd, London; 1991. p. 45-9
   Google Scholar
• Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J Mol Endocrinol 1994;13:331-7
   PubMed Web of Science ®Google Scholar
• Wang L, Ellsworth KA, Moon I, Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res 2010;70:319-28
   PubMed Web of Science ®Google Scholar
• Miller WR, Anderson TJ, Hawkins RA, Neoadjuvant endocrine treatment: the Edinburgh experience. In: Dowsett M, Howell A, editors, Primary medical therapy for breast cancer: clinical and biological aspects. Elsevier, Amsterdam; 1999. p. 89-99
   Google Scholar
• Fuqua SA, Cui Y. Estrogen and progesterone receptor isoforms: clinical significance in breast cancer. Breast Cancer Res Treat 2004;87(Suppl 1):3-10
   Google Scholar
• Bunone G, Briand PA, Miksicek RJ, Picard D. Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. EMBO J 1996;15:2174-83
   PubMed Web of Science ®Google Scholar
• Dowsett M, Harper-Wynne C, Boeddinghaus I, HER-2 amplification impedes the antiproliferative effects of hormone therapy in estrogen receptor-positive primary breast cancer. Cancer Res 2001;61:8452-8
   PubMed Web of Science ®Google Scholar
• Ellis MJ, Tao Y, Young O, Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006;24:3019-25
   PubMed Web of Science ®Google Scholar
• Miller WR, Anderson TJ, White S, Growth factor signalling in clinical breast cancer and its impact on response to conventional therapies: the Edinburgh experience. Endocr Relat Cancer 2005;12(Suppl 1):119-23
   PubMedGoogle Scholar
• Zhu L, Chow LWC, Loo WTY, Her2/neu expression predicts the response to antiaromatase neoadjuvant therapy in primary breast cancer: subgroup analysis from Celecoxib antiaromatase neoadjuvant trial. Clin Cancer Res 2004;10:4639-44
   PubMedGoogle Scholar
• Lal P, Tan LK, Chen B. Correlation of HER-2 status with estrogen and progesteronereceptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 2005;123:541-6
   PubMed Web of Science ®Google Scholar
• Johnston SRD, Martin LA, Head J, Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2007;106:180-6
   PubMed Web of Science ®Google Scholar
• Robertson JF. Oestrogen receptor: a stable phenotype in breast cancer. Br J Cancer 1996;73:5-12
   PubMedGoogle Scholar
• Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998;11:155-68
   PubMed Web of Science ®Google Scholar